Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#npk07 *,#npk07 *::before,#npk07 *::after{box-sizing:border-box;margin:0;padding:0}\n#npk07{\n --ob:#1A5F7A;--ob-light:#236E8C;--ob-pale:#E6F3F7;--ob-dark:#114455;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#0F2A35;--ink-mid:#2A4D5A;--ink-soft:#5A7D8A;\n --line:#B8D8E3;--cream:#F2F8FA;--warm:#F8FCFD;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#npk07 .mr-header{background:linear-gradient(135deg,var(--ob-dark) 0%,var(--ob) 60%,var(--ob-light) 100%);color:#E4F4F9;padding:36px 24px 30px;text-align:center;position:relative;overflow:hidden;}\n#npk07 .mr-header::before{content:'';position:absolute;inset:0;background:repeating-linear-gradient(45deg,transparent,transparent 18px,rgba(255,255,255,0.03) 18px,rgba(255,255,255,0.03) 19px);}\n#npk07 .mr-eyebrow{font-size:0.66rem;letter-spacing:0.22em;text-transform:uppercase;font-weight:700;opacity:0.6;margin-bottom:10px;position:relative;}\n#npk07 .mr-series-tag{display:inline-block;background:rgba(255,255,255,0.12);border:1px solid rgba(255,255,255,0.2);border-radius:4px;padding:2px 10px;font-size:0.64rem;letter-spacing:0.14em;text-transform:uppercase;font-weight:700;margin-bottom:14px;position:relative;}\n#npk07 .mr-title{font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700;line-height:1.2;margin-bottom:6px;position:relative;}\n#npk07 .mr-title em{font-style:italic;font-weight:400;opacity:0.85}\n#npk07 .mr-subtitle{font-size:0.82rem;opacity:0.65;margin-top:8px;font-style:italic;position:relative;}\n#npk07 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap;position:relative;}\n#npk07 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.72rem;}\n#npk07 .mr-sentinel{height:1px}\n#npk07 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(15,42,53,0.1);padding:9px 16px;display:none;}\n#npk07 .mr-progress.visible{display:block}\n#npk07 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#npk07 .mr-pips{display:flex;align-items:center;justify-content:center}\n#npk07 .mr-pip-wrap{display:flex;align-items:center}\n#npk07 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#npk07 .mr-pip-line.done{background:var(--ob)}\n#npk07 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0;}\n#npk07 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk07 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk07 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#npk07 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ob);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 8px rgba(15,42,53,0.07);}\n#npk07 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#npk07 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ob);opacity:0.14;line-height:1;margin-top:-2px;flex-shrink:0;}\n#npk07 .mr-meta{flex:1}\n#npk07 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob);opacity:0.8;margin-bottom:5px;}\n#npk07 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#npk07 .mr-stem strong{font-weight:600}\n#npk07 .mr-stem em{font-style:italic}\n#npk07 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#npk07 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#npk07 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent;}\n#npk07 .mr-opt:hover{border-color:var(--ob);background:var(--ob-pale)}\n#npk07 .mr-opt.locked{cursor:default}\n#npk07 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#npk07 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#npk07 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#npk07 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#npk07 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#npk07 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#npk07 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#npk07 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s;}\n#npk07 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk07 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk07 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#npk07 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#npk07 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#npk07 .mr-exp{display:none;border-top:1px solid #9CCFDF;background:linear-gradient(180deg,#D4EEF7 0%,#EAF5FA 100%);padding:13px 20px 15px;}\n#npk07 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob-dark);margin-bottom:6px;}\n#npk07 .mr-exp-text{font-size:0.86rem;color:#0F2A35;line-height:1.7}\n#npk07 .mr-exp-text strong{font-weight:600}\n#npk07 .mr-exp-text em{font-style:italic}\n#npk07 .mr-exp-text .calc{display:block;background:rgba(26,95,122,0.08);border-left:3px solid var(--ob);border-radius:0 4px 4px 0;padding:6px 10px;margin:8px 0;font-family:Georgia,serif;font-size:0.84rem;color:var(--ob-dark);}\n#npk07 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#npk07 .mr-btn{background:var(--ob);color:#E4F4F9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(26,95,122,0.32);}\n#npk07 .mr-btn:hover{background:var(--ob-dark)}\n#npk07 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ob);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(15,42,53,0.08);overflow:hidden;}\n#npk07 .mr-score-in{padding:28px 24px;text-align:center}\n#npk07 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600;}\n#npk07 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ob) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative;}\n#npk07 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm);}\n#npk07 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#npk07 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ob)}\n#npk07 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#npk07 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#npk07 .mr-score-net{font-size:0.9rem;color:var(--ob);font-weight:600;margin-bottom:4px}\n#npk07 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#npk07 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#npk07 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#npk07 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#npk07 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#npk07 .mr-band-s{background:var(--ob-pale);color:var(--ob)}\n#npk07 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ob);color:var(--ob);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer;}\n#npk07 .mr-retry:hover{background:var(--ob);color:#E4F4F9}\n#npk07 .mr-series-end{text-align:center;padding:24px 16px 0;font-size:0.86rem;color:var(--ink-soft);font-style:italic;border-top:1px solid var(--line);margin-top:8px;}\n#npk07 .mr-series-end strong{color:var(--ob);font-style:normal;}\n@media(max-width:480px){\n #npk07 .mr-title{font-size:1.4rem}\n #npk07 .mr-num{font-size:1.7rem}\n #npk07 .mr-stem{font-size:0.9rem}\n #npk07 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"npk07\">\n\n <div class=\"mr-header\">\n <div class=\"mr-series-tag\">Numerical Series · Pharmacokinetics<\/div>\n <div class=\"mr-eyebrow\">Morning Rounds · Round 07 of 07<\/div>\n <div class=\"mr-title\">Bioavailability, Protein Binding<br><em>& Special Populations<\/em><\/div>\n <div class=\"mr-subtitle\">Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Questions<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"npk07-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"npk07-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"npk07-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"npk07-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"npk07-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"npk07-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Series Complete<\/div>\n <div class=\"mr-ring\" id=\"npk07-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"npk07-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Round 07 — Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"npk07-net\"><\/div>\n <div class=\"mr-verdict\" id=\"npk07-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"npk07-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"npk07-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"npk07-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"npk07-retry\">↻ Retry This Round<\/button>\n <div class=\"mr-series-end\">\n <strong>All 7 Rounds Complete.<\/strong><br>\n You have covered zero & first-order kinetics, half-life, Vd, loading dose,\n clearance, steady state, therapeutic index, and special populations.\n The Summative Revision awaits.\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'npk07';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [\n\n {\n id: 1,\n tag: 'First-Pass Metabolism — Oral vs Sublingual',\n stem: 'Glyceryl trinitrate (GTN) has an oral bioavailability of <strong><1%<\/strong> due to extensive first-pass metabolism, yet it is highly effective when given <strong>sublingually<\/strong>. A patient swallows a sublingual GTN tablet by mistake instead of placing it under the tongue. What is the pharmacokinetic consequence?',\n correct: 'Negligible systemic effect; swallowed GTN undergoes near-complete hepatic first-pass metabolism, leaving <1% bioavailability \u2014 the therapeutic dose never reaches systemic circulation in meaningful concentration',\n opts: [\n 'Negligible systemic effect; swallowed GTN undergoes near-complete hepatic first-pass metabolism, leaving <1% bioavailability \u2014 the therapeutic dose never reaches systemic circulation in meaningful concentration',\n 'Identical effect to sublingual administration; once absorbed from the GI tract GTN reaches the same systemic circulation regardless of route',\n 'Enhanced effect; oral administration delays absorption, producing a prolonged plateau concentration superior to the rapid peak-and-trough of sublingual dosing',\n 'Toxic effect; oral GTN bypasses the liver entirely via the portal vein and reaches systemic circulation at full dose, causing dangerous hypotension'\n ],\n exp: 'Sublingual route drains into the <strong>superior vena cava directly<\/strong>, bypassing the liver entirely. The drug reaches systemic circulation intact.<br><br>Swallowed GTN takes the oral route: absorbed from gut → <strong>portal vein → liver → first-pass metabolism → <1% survives<\/strong>.<span class=\"calc\">Sublingual bioavailability: ~80%<br>Oral bioavailability: <1%<br>Same molecule. Entirely different fate.<\/span>This is why GTN is never given as a standard oral tablet for acute angina. The sublingual, transdermal (patch), and IV routes all circumvent first-pass. Trap D perfectly inverts the anatomy — the portal vein is <em>where<\/em> first-pass happens, not how it is bypassed. Trap B ignores first-pass entirely. Clinically: if a patient swallows their GTN tablet, they get essentially no effect. Prescribe again sublingually.'\n },\n\n {\n id: 2,\n tag: 'Protein Binding — Free Drug & Drug Displacement',\n stem: 'Warfarin is <strong>99% protein-bound<\/strong> to albumin. A patient stabilised on warfarin is started on <strong>phenylbutazone<\/strong>, which displaces warfarin from albumin binding sites. Before any change in clearance occurs, what is the immediate consequence of displacement?',\n correct: 'Free warfarin fraction rises from 1% to approximately 2%, doubling the pharmacologically active drug concentration and causing a transient but potentially dangerous increase in anticoagulant effect',\n opts: [\n 'Free warfarin fraction rises from 1% to approximately 2%, doubling the pharmacologically active drug concentration and causing a transient but potentially dangerous increase in anticoagulant effect',\n 'Total plasma warfarin concentration doubles immediately because displaced warfarin cannot re-enter tissues and accumulates in plasma',\n 'No clinically significant effect occurs; protein binding is a reversible equilibrium and displaced drug is immediately rebound to other albumin molecules',\n 'Warfarin is rapidly eliminated because free drug is the only form available for renal filtration, so displacement accelerates clearance and reduces anticoagulant effect'\n ],\n exp: 'Protein binding is the pharmacokinetic concept most likely to produce a <strong>paradoxical-seeming<\/strong> exam answer.<br><br>Only <strong>free (unbound) drug<\/strong> is pharmacologically active, crosses membranes, and is available for elimination. Bound drug is pharmacologically inert — it is a reservoir.<span class=\"calc\">Warfarin normally: 99% bound, 1% free<br>After displacement: say 98% bound, 2% free<br>Free fraction doubles: 1% → 2%<\/span>Doubling of free drug = doubled pharmacological effect = dangerous bleeding risk on the same total dose. This is a well-documented interaction: phenylbutazone, aspirin, NSAIDs, sulfonamides all displace warfarin. Note: the effect is <em>transient<\/em> — once clearance catches up (free drug is cleared faster), a new steady state is reached. But the window of danger is real. Trap C is wrong: even a small displacement of a highly protein-bound drug causes clinically significant free-fraction changes. Trap D is partially correct mechanistically but wrong about net effect — the transient spike in free drug occurs before clearance compensates.'\n },\n\n {\n id: 3,\n tag: 'Special Populations — Neonates & Drug Handling',\n stem: 'A neonate (28-day-old, 3.2 kg) requires antibiotic therapy. Compared to an adult, neonatal pharmacokinetics differs in several important ways. Which of the following correctly describes neonatal drug handling and its dosing implication?',\n correct: 'Neonates have reduced renal GFR (~30% of adult values), immature hepatic enzyme activity, and higher total body water (80% vs 60%), resulting in prolonged half-lives, larger weight-based Vd for water-soluble drugs, and requirement for extended dosing intervals',\n opts: [\n 'Neonates have reduced renal GFR (~30% of adult values), immature hepatic enzyme activity, and higher total body water (80% vs 60%), resulting in prolonged half-lives, larger weight-based Vd for water-soluble drugs, and requirement for extended dosing intervals',\n 'Neonates have enhanced renal clearance due to proportionally larger kidneys relative to body weight, requiring higher mg\/kg doses and shorter dosing intervals than adults',\n 'Neonates handle drugs identically to adults on a mg\/kg basis; the only adjustment needed is to scale the adult dose proportionally down to the neonate\\'s body weight',\n 'Neonatal hepatic enzyme activity is mature at birth and exceeds adult levels in the first month of life, making neonates more efficient at metabolising drugs than older children'\n ],\n exp: 'Neonatal pharmacokinetics departs from the adult in every direction:<br><br><strong>Absorption:<\/strong> gastric pH higher (less acid) → affects oral drug stability; slower gastric emptying.<br><br><strong>Distribution:<\/strong> higher total body water (80% vs adult 60%) → water-soluble drugs have <em>larger<\/em> Vd per kg → higher mg\/kg loading dose needed for water-soluble drugs. Lower albumin and different binding proteins → higher free fraction of protein-bound drugs.<br><br><strong>Metabolism:<\/strong> CYP450 enzymes <strong>immature at birth<\/strong>; reach adult activity at ~6 months to 1 year. Glucuronidation particularly deficient → chloramphenicol grey baby syndrome (accumulation of unconjugated drug).<span class=\"calc\">Renal GFR at birth: ~30% of adult<br>Reaches adult GFR: by 6–12 months<br>Consequence: prolonged t½ for renally-excreted drugs<\/span>All these factors together = <strong>longer half-lives, accumulation risk, need for extended dosing intervals<\/strong>. Gentamicin in neonates is given every 36–48 hours vs every 8 hours in adults, precisely because of immature renal clearance.'\n },\n\n {\n id: 4,\n tag: 'Special Populations — Elderly & Pharmacokinetic Changes',\n stem: 'An 80-year-old woman (45 kg, serum creatinine <strong>90 μmol\/L<\/strong>) is prescribed gentamicin. Her creatinine appears normal, but her calculated creatinine clearance (Cockcroft-Gault) is <strong>22 mL\/min<\/strong>. The standard adult dose is 5 mg\/kg every 24 hours. Which statement correctly explains the discrepancy and guides dosing?',\n correct: 'In the elderly, reduced muscle mass lowers creatinine production, so serum creatinine underestimates the degree of renal impairment; calculated CrCl of 22 mL\/min mandates significant dose reduction and interval extension',\n opts: [\n 'In the elderly, reduced muscle mass lowers creatinine production, so serum creatinine underestimates the degree of renal impairment; calculated CrCl of 22 mL\/min mandates significant dose reduction and interval extension',\n 'A serum creatinine of 90 μmol\/L is within normal limits, confirming normal renal function; the calculated CrCl of 22 mL\/min is a mathematical artefact of the Cockcroft-Gault formula and can be disregarded',\n 'The discrepancy is explained by increased muscle mass in the elderly increasing creatinine production, which elevates serum creatinine and makes the Cockcroft-Gault formula unreliable',\n 'Gentamicin dose should be increased in the elderly because reduced albumin binding increases the free fraction available for tissue penetration, necessitating higher doses to achieve therapeutic levels'\n ],\n exp: 'This is the <strong>creatinine trap in the elderly<\/strong> — a high-yield clinical pharmacology concept.<br><br>Creatinine is a breakdown product of muscle. The elderly have <strong>reduced muscle mass (sarcopenia)<\/strong> → less creatinine produced → lower serum creatinine → serum Cr appears \"normal\" despite significantly impaired GFR.<span class=\"calc\">Cockcroft-Gault CrCl = [(140 − age) × weight] ÷ (72 × serum Cr)<br>For this patient: [(140−80) × 45] ÷ (72 × 1.02)<br>≈ 2700 ÷ 73.4 ≈ <strong>22 mL\/min<\/strong><\/span>A CrCl of 22 mL\/min is <strong>severe renal impairment<\/strong> by standard classification (<30 mL\/min). Gentamicin at standard dose would accumulate, causing nephrotoxicity and ototoxicity. Dose must be reduced and interval extended significantly. The lesson: <strong>never trust serum creatinine alone in the elderly<\/strong>. Always calculate CrCl. Trap D is dangerous and backwards: gentamicin is not protein-bound in any significant amount, and reduced clearance always mandates dose reduction, not increase.'\n },\n\n {\n id: 5,\n tag: 'Special Populations — Pregnancy & Drug Distribution',\n stem: 'A woman at <strong>32 weeks gestation<\/strong> requires treatment with a drug that is <strong>70% protein-bound<\/strong> at baseline. During pregnancy, plasma albumin falls by approximately <strong>20%<\/strong> and total plasma volume increases by <strong>40%<\/strong>. Which statement best predicts the pharmacokinetic consequences for this drug in this patient?',\n correct: 'Free drug fraction increases due to reduced albumin, while the expanded plasma volume dilutes drug concentration; both effects combine to alter Vd and potentially reduce efficacy at standard doses \u2014 dose adjustment guided by therapeutic monitoring is prudent',\n opts: [\n 'Free drug fraction increases due to reduced albumin, while the expanded plasma volume dilutes drug concentration; both effects combine to alter Vd and possibly reduce efficacy at standard doses \u2014 dose adjustment guided by therapeutic monitoring is prudent',\n 'Reduced albumin in pregnancy is fully compensated by the 40% increase in plasma volume, so total drug concentration and free fraction remain unchanged and no dose adjustment is required',\n 'The increase in plasma volume is the dominant effect; it dilutes drug concentration and reduces the free fraction, making the drug less effective and potentially toxic due to reduced clearance',\n 'Pregnancy has no clinically significant effect on protein binding for drugs that are less than 90% bound; only highly protein-bound drugs (>95%) require adjustment'\n ],\n exp: 'Pregnancy is a pharmacokinetic storm — virtually every parameter changes:<br><br><strong>Plasma volume<\/strong> +40% → dilution effect → lower plasma concentration for same dose → larger Vd → may need <em>higher<\/em> doses.<br><br><strong>Albumin<\/strong> ↓20% → reduced binding sites → free fraction rises → more pharmacologically active drug → but also more available for elimination.<span class=\"calc\">Baseline: 70% bound, 30% free<br>With 20% albumin fall: binding capacity reduced<br>Free fraction rises (exact amount depends on drug-specific binding constants)<br>Simultaneously: dilution from expanded plasma volume lowers total Cp<\/span><strong>Net effect:<\/strong> unpredictable without drug-specific data. These effects push in opposite directions and may partially cancel or compound. For NTI drugs (phenytoin, lithium, digoxin), pregnancy nearly always requires dose adjustment upward and therapeutic drug monitoring. Trap B (full compensation) is pharmacologically implausible — volume expansion dilutes drug but does not restore albumin binding sites. Trap C misassigns the direction of free-fraction change with volume expansion. The exam-safe answer: <strong>monitor levels, do not assume standard doses are adequate in late pregnancy<\/strong>.'\n }\n\n ];\n\n var answers = {}, answered = 0, shuffled = {}, done = false;\n\n function gid(s) { return document.getElementById(NS + '-' + s); }\n function byId(s) { return document.getElementById(s); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, t;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n t = a[i]; a[i] = a[j]; a[j] = t;\n }\n return a;\n }\n\n function countVal(v) {\n var n = 0, k;\n for (k in answers) { if (answers[k] === v) n++; }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, j, optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = byId(NS + '-pl' + qid);\n if (pl) { pl.className = 'mr-pip-line done'; }\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#1A5F7A ' + disp + '%, #B8D8E3 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [\n [5, 'Series closed perfectly. GTN anatomy, warfarin displacement, neonatal kinetics, the creatinine trap, pregnancy \\u2014 all owned.'],\n [4, 'Strong finish. One concept to consolidate \\u2014 the debrief has it. Seven rounds done.'],\n [3, 'Good base across the series. The creatinine trap (Q4) and protein binding displacement (Q2) are the ones to revisit before the Summative.'],\n [2, 'Two solid concepts to re-read: the portal vein anatomy in Q1 and the elderly creatinine trap in Q4. Both are exam staples.'],\n [0, 'Start with Q1 \\u2014 the GTN anatomy question is pure logic once you know the portal vein route. Then build from there.']\n ];\n gid('verdict').textContent = verdicts[4][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n<\/html>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,79],"tags":[83],"class_list":["post-37355","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-pharmacology","tag-neet-pg"],"yoast_head":"\n<title>Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… \" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-23T05:09:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-23T05:09:46+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations\",\"datePublished\":\"2026-08-23T05:09:06+00:00\",\"dateModified\":\"2026-08-23T05:09:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"},\"wordCount\":83,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"Pharmacology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\",\"name\":\"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-08-23T05:09:06+00:00\",\"dateModified\":\"2026-08-23T05:09:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","og_description":"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… ","og_url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","og_site_name":"atsixty","article_published_time":"2026-08-23T05:09:06+00:00","article_modified_time":"2026-08-23T05:09:46+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations","datePublished":"2026-08-23T05:09:06+00:00","dateModified":"2026-08-23T05:09:46+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"},"wordCount":83,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["NEET-PG"],"articleSection":["Morning Rounds","Pharmacology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","name":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-08-23T05:09:06+00:00","dateModified":"2026-08-23T05:09:46+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37355"}],"version-history":[{"count":2,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355\/revisions"}],"predecessor-version":[{"id":37357,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355\/revisions\/37357"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":37355,"date":"2026-08-23T10:39:06","date_gmt":"2026-08-23T05:09:06","guid":{"rendered":"https:\/\/atsixty.com\/?p=37355"},"modified":"2026-08-23T10:39:46","modified_gmt":"2026-08-23T05:09:46","slug":"pharmacokinetics-bioavailability-protein-binding-special-populations","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","title":{"rendered":"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations"},"content":{"rendered":"\n\n\n\n\n\n\n\nMorning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#npk07 *,#npk07 *::before,#npk07 *::after{box-sizing:border-box;margin:0;padding:0}\n#npk07{\n --ob:#1A5F7A;--ob-light:#236E8C;--ob-pale:#E6F3F7;--ob-dark:#114455;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#0F2A35;--ink-mid:#2A4D5A;--ink-soft:#5A7D8A;\n --line:#B8D8E3;--cream:#F2F8FA;--warm:#F8FCFD;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#npk07 .mr-header{background:linear-gradient(135deg,var(--ob-dark) 0%,var(--ob) 60%,var(--ob-light) 100%);color:#E4F4F9;padding:36px 24px 30px;text-align:center;position:relative;overflow:hidden;}\n#npk07 .mr-header::before{content:'';position:absolute;inset:0;background:repeating-linear-gradient(45deg,transparent,transparent 18px,rgba(255,255,255,0.03) 18px,rgba(255,255,255,0.03) 19px);}\n#npk07 .mr-eyebrow{font-size:0.66rem;letter-spacing:0.22em;text-transform:uppercase;font-weight:700;opacity:0.6;margin-bottom:10px;position:relative;}\n#npk07 .mr-series-tag{display:inline-block;background:rgba(255,255,255,0.12);border:1px solid rgba(255,255,255,0.2);border-radius:4px;padding:2px 10px;font-size:0.64rem;letter-spacing:0.14em;text-transform:uppercase;font-weight:700;margin-bottom:14px;position:relative;}\n#npk07 .mr-title{font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700;line-height:1.2;margin-bottom:6px;position:relative;}\n#npk07 .mr-title em{font-style:italic;font-weight:400;opacity:0.85}\n#npk07 .mr-subtitle{font-size:0.82rem;opacity:0.65;margin-top:8px;font-style:italic;position:relative;}\n#npk07 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap;position:relative;}\n#npk07 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.72rem;}\n#npk07 .mr-sentinel{height:1px}\n#npk07 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(15,42,53,0.1);padding:9px 16px;display:none;}\n#npk07 .mr-progress.visible{display:block}\n#npk07 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#npk07 .mr-pips{display:flex;align-items:center;justify-content:center}\n#npk07 .mr-pip-wrap{display:flex;align-items:center}\n#npk07 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#npk07 .mr-pip-line.done{background:var(--ob)}\n#npk07 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0;}\n#npk07 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk07 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk07 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#npk07 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ob);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 8px rgba(15,42,53,0.07);}\n#npk07 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#npk07 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ob);opacity:0.14;line-height:1;margin-top:-2px;flex-shrink:0;}\n#npk07 .mr-meta{flex:1}\n#npk07 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob);opacity:0.8;margin-bottom:5px;}\n#npk07 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#npk07 .mr-stem strong{font-weight:600}\n#npk07 .mr-stem em{font-style:italic}\n#npk07 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#npk07 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#npk07 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent;}\n#npk07 .mr-opt:hover{border-color:var(--ob);background:var(--ob-pale)}\n#npk07 .mr-opt.locked{cursor:default}\n#npk07 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#npk07 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#npk07 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#npk07 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#npk07 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#npk07 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#npk07 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#npk07 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s;}\n#npk07 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#npk07 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#npk07 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#npk07 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#npk07 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#npk07 .mr-exp{display:none;border-top:1px solid #9CCFDF;background:linear-gradient(180deg,#D4EEF7 0%,#EAF5FA 100%);padding:13px 20px 15px;}\n#npk07 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ob-dark);margin-bottom:6px;}\n#npk07 .mr-exp-text{font-size:0.86rem;color:#0F2A35;line-height:1.7}\n#npk07 .mr-exp-text strong{font-weight:600}\n#npk07 .mr-exp-text em{font-style:italic}\n#npk07 .mr-exp-text .calc{display:block;background:rgba(26,95,122,0.08);border-left:3px solid var(--ob);border-radius:0 4px 4px 0;padding:6px 10px;margin:8px 0;font-family:Georgia,serif;font-size:0.84rem;color:var(--ob-dark);}\n#npk07 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#npk07 .mr-btn{background:var(--ob);color:#E4F4F9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(26,95,122,0.32);}\n#npk07 .mr-btn:hover{background:var(--ob-dark)}\n#npk07 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ob);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(15,42,53,0.08);overflow:hidden;}\n#npk07 .mr-score-in{padding:28px 24px;text-align:center}\n#npk07 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600;}\n#npk07 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ob) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative;}\n#npk07 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm);}\n#npk07 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#npk07 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ob)}\n#npk07 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#npk07 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#npk07 .mr-score-net{font-size:0.9rem;color:var(--ob);font-weight:600;margin-bottom:4px}\n#npk07 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#npk07 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#npk07 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#npk07 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#npk07 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#npk07 .mr-band-s{background:var(--ob-pale);color:var(--ob)}\n#npk07 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ob);color:var(--ob);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer;}\n#npk07 .mr-retry:hover{background:var(--ob);color:#E4F4F9}\n#npk07 .mr-series-end{text-align:center;padding:24px 16px 0;font-size:0.86rem;color:var(--ink-soft);font-style:italic;border-top:1px solid var(--line);margin-top:8px;}\n#npk07 .mr-series-end strong{color:var(--ob);font-style:normal;}\n@media(max-width:480px){\n #npk07 .mr-title{font-size:1.4rem}\n #npk07 .mr-num{font-size:1.7rem}\n #npk07 .mr-stem{font-size:0.9rem}\n #npk07 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"npk07\">\n\n <div class=\"mr-header\">\n <div class=\"mr-series-tag\">Numerical Series · Pharmacokinetics<\/div>\n <div class=\"mr-eyebrow\">Morning Rounds · Round 07 of 07<\/div>\n <div class=\"mr-title\">Bioavailability, Protein Binding<br><em>& Special Populations<\/em><\/div>\n <div class=\"mr-subtitle\">Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Questions<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"npk07-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"npk07-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"npk07-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"npk07-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"npk07-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"npk07-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Series Complete<\/div>\n <div class=\"mr-ring\" id=\"npk07-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"npk07-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Round 07 — Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"npk07-net\"><\/div>\n <div class=\"mr-verdict\" id=\"npk07-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"npk07-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"npk07-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"npk07-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"npk07-retry\">↻ Retry This Round<\/button>\n <div class=\"mr-series-end\">\n <strong>All 7 Rounds Complete.<\/strong><br>\n You have covered zero & first-order kinetics, half-life, Vd, loading dose,\n clearance, steady state, therapeutic index, and special populations.\n The Summative Revision awaits.\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'npk07';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [\n\n {\n id: 1,\n tag: 'First-Pass Metabolism — Oral vs Sublingual',\n stem: 'Glyceryl trinitrate (GTN) has an oral bioavailability of <strong><1%<\/strong> due to extensive first-pass metabolism, yet it is highly effective when given <strong>sublingually<\/strong>. A patient swallows a sublingual GTN tablet by mistake instead of placing it under the tongue. What is the pharmacokinetic consequence?',\n correct: 'Negligible systemic effect; swallowed GTN undergoes near-complete hepatic first-pass metabolism, leaving <1% bioavailability \u2014 the therapeutic dose never reaches systemic circulation in meaningful concentration',\n opts: [\n 'Negligible systemic effect; swallowed GTN undergoes near-complete hepatic first-pass metabolism, leaving <1% bioavailability \u2014 the therapeutic dose never reaches systemic circulation in meaningful concentration',\n 'Identical effect to sublingual administration; once absorbed from the GI tract GTN reaches the same systemic circulation regardless of route',\n 'Enhanced effect; oral administration delays absorption, producing a prolonged plateau concentration superior to the rapid peak-and-trough of sublingual dosing',\n 'Toxic effect; oral GTN bypasses the liver entirely via the portal vein and reaches systemic circulation at full dose, causing dangerous hypotension'\n ],\n exp: 'Sublingual route drains into the <strong>superior vena cava directly<\/strong>, bypassing the liver entirely. The drug reaches systemic circulation intact.<br><br>Swallowed GTN takes the oral route: absorbed from gut → <strong>portal vein → liver → first-pass metabolism → <1% survives<\/strong>.<span class=\"calc\">Sublingual bioavailability: ~80%<br>Oral bioavailability: <1%<br>Same molecule. Entirely different fate.<\/span>This is why GTN is never given as a standard oral tablet for acute angina. The sublingual, transdermal (patch), and IV routes all circumvent first-pass. Trap D perfectly inverts the anatomy — the portal vein is <em>where<\/em> first-pass happens, not how it is bypassed. Trap B ignores first-pass entirely. Clinically: if a patient swallows their GTN tablet, they get essentially no effect. Prescribe again sublingually.'\n },\n\n {\n id: 2,\n tag: 'Protein Binding — Free Drug & Drug Displacement',\n stem: 'Warfarin is <strong>99% protein-bound<\/strong> to albumin. A patient stabilised on warfarin is started on <strong>phenylbutazone<\/strong>, which displaces warfarin from albumin binding sites. Before any change in clearance occurs, what is the immediate consequence of displacement?',\n correct: 'Free warfarin fraction rises from 1% to approximately 2%, doubling the pharmacologically active drug concentration and causing a transient but potentially dangerous increase in anticoagulant effect',\n opts: [\n 'Free warfarin fraction rises from 1% to approximately 2%, doubling the pharmacologically active drug concentration and causing a transient but potentially dangerous increase in anticoagulant effect',\n 'Total plasma warfarin concentration doubles immediately because displaced warfarin cannot re-enter tissues and accumulates in plasma',\n 'No clinically significant effect occurs; protein binding is a reversible equilibrium and displaced drug is immediately rebound to other albumin molecules',\n 'Warfarin is rapidly eliminated because free drug is the only form available for renal filtration, so displacement accelerates clearance and reduces anticoagulant effect'\n ],\n exp: 'Protein binding is the pharmacokinetic concept most likely to produce a <strong>paradoxical-seeming<\/strong> exam answer.<br><br>Only <strong>free (unbound) drug<\/strong> is pharmacologically active, crosses membranes, and is available for elimination. Bound drug is pharmacologically inert — it is a reservoir.<span class=\"calc\">Warfarin normally: 99% bound, 1% free<br>After displacement: say 98% bound, 2% free<br>Free fraction doubles: 1% → 2%<\/span>Doubling of free drug = doubled pharmacological effect = dangerous bleeding risk on the same total dose. This is a well-documented interaction: phenylbutazone, aspirin, NSAIDs, sulfonamides all displace warfarin. Note: the effect is <em>transient<\/em> — once clearance catches up (free drug is cleared faster), a new steady state is reached. But the window of danger is real. Trap C is wrong: even a small displacement of a highly protein-bound drug causes clinically significant free-fraction changes. Trap D is partially correct mechanistically but wrong about net effect — the transient spike in free drug occurs before clearance compensates.'\n },\n\n {\n id: 3,\n tag: 'Special Populations — Neonates & Drug Handling',\n stem: 'A neonate (28-day-old, 3.2 kg) requires antibiotic therapy. Compared to an adult, neonatal pharmacokinetics differs in several important ways. Which of the following correctly describes neonatal drug handling and its dosing implication?',\n correct: 'Neonates have reduced renal GFR (~30% of adult values), immature hepatic enzyme activity, and higher total body water (80% vs 60%), resulting in prolonged half-lives, larger weight-based Vd for water-soluble drugs, and requirement for extended dosing intervals',\n opts: [\n 'Neonates have reduced renal GFR (~30% of adult values), immature hepatic enzyme activity, and higher total body water (80% vs 60%), resulting in prolonged half-lives, larger weight-based Vd for water-soluble drugs, and requirement for extended dosing intervals',\n 'Neonates have enhanced renal clearance due to proportionally larger kidneys relative to body weight, requiring higher mg\/kg doses and shorter dosing intervals than adults',\n 'Neonates handle drugs identically to adults on a mg\/kg basis; the only adjustment needed is to scale the adult dose proportionally down to the neonate\\'s body weight',\n 'Neonatal hepatic enzyme activity is mature at birth and exceeds adult levels in the first month of life, making neonates more efficient at metabolising drugs than older children'\n ],\n exp: 'Neonatal pharmacokinetics departs from the adult in every direction:<br><br><strong>Absorption:<\/strong> gastric pH higher (less acid) → affects oral drug stability; slower gastric emptying.<br><br><strong>Distribution:<\/strong> higher total body water (80% vs adult 60%) → water-soluble drugs have <em>larger<\/em> Vd per kg → higher mg\/kg loading dose needed for water-soluble drugs. Lower albumin and different binding proteins → higher free fraction of protein-bound drugs.<br><br><strong>Metabolism:<\/strong> CYP450 enzymes <strong>immature at birth<\/strong>; reach adult activity at ~6 months to 1 year. Glucuronidation particularly deficient → chloramphenicol grey baby syndrome (accumulation of unconjugated drug).<span class=\"calc\">Renal GFR at birth: ~30% of adult<br>Reaches adult GFR: by 6–12 months<br>Consequence: prolonged t½ for renally-excreted drugs<\/span>All these factors together = <strong>longer half-lives, accumulation risk, need for extended dosing intervals<\/strong>. Gentamicin in neonates is given every 36–48 hours vs every 8 hours in adults, precisely because of immature renal clearance.'\n },\n\n {\n id: 4,\n tag: 'Special Populations — Elderly & Pharmacokinetic Changes',\n stem: 'An 80-year-old woman (45 kg, serum creatinine <strong>90 μmol\/L<\/strong>) is prescribed gentamicin. Her creatinine appears normal, but her calculated creatinine clearance (Cockcroft-Gault) is <strong>22 mL\/min<\/strong>. The standard adult dose is 5 mg\/kg every 24 hours. Which statement correctly explains the discrepancy and guides dosing?',\n correct: 'In the elderly, reduced muscle mass lowers creatinine production, so serum creatinine underestimates the degree of renal impairment; calculated CrCl of 22 mL\/min mandates significant dose reduction and interval extension',\n opts: [\n 'In the elderly, reduced muscle mass lowers creatinine production, so serum creatinine underestimates the degree of renal impairment; calculated CrCl of 22 mL\/min mandates significant dose reduction and interval extension',\n 'A serum creatinine of 90 μmol\/L is within normal limits, confirming normal renal function; the calculated CrCl of 22 mL\/min is a mathematical artefact of the Cockcroft-Gault formula and can be disregarded',\n 'The discrepancy is explained by increased muscle mass in the elderly increasing creatinine production, which elevates serum creatinine and makes the Cockcroft-Gault formula unreliable',\n 'Gentamicin dose should be increased in the elderly because reduced albumin binding increases the free fraction available for tissue penetration, necessitating higher doses to achieve therapeutic levels'\n ],\n exp: 'This is the <strong>creatinine trap in the elderly<\/strong> — a high-yield clinical pharmacology concept.<br><br>Creatinine is a breakdown product of muscle. The elderly have <strong>reduced muscle mass (sarcopenia)<\/strong> → less creatinine produced → lower serum creatinine → serum Cr appears \"normal\" despite significantly impaired GFR.<span class=\"calc\">Cockcroft-Gault CrCl = [(140 − age) × weight] ÷ (72 × serum Cr)<br>For this patient: [(140−80) × 45] ÷ (72 × 1.02)<br>≈ 2700 ÷ 73.4 ≈ <strong>22 mL\/min<\/strong><\/span>A CrCl of 22 mL\/min is <strong>severe renal impairment<\/strong> by standard classification (<30 mL\/min). Gentamicin at standard dose would accumulate, causing nephrotoxicity and ototoxicity. Dose must be reduced and interval extended significantly. The lesson: <strong>never trust serum creatinine alone in the elderly<\/strong>. Always calculate CrCl. Trap D is dangerous and backwards: gentamicin is not protein-bound in any significant amount, and reduced clearance always mandates dose reduction, not increase.'\n },\n\n {\n id: 5,\n tag: 'Special Populations — Pregnancy & Drug Distribution',\n stem: 'A woman at <strong>32 weeks gestation<\/strong> requires treatment with a drug that is <strong>70% protein-bound<\/strong> at baseline. During pregnancy, plasma albumin falls by approximately <strong>20%<\/strong> and total plasma volume increases by <strong>40%<\/strong>. Which statement best predicts the pharmacokinetic consequences for this drug in this patient?',\n correct: 'Free drug fraction increases due to reduced albumin, while the expanded plasma volume dilutes drug concentration; both effects combine to alter Vd and potentially reduce efficacy at standard doses \u2014 dose adjustment guided by therapeutic monitoring is prudent',\n opts: [\n 'Free drug fraction increases due to reduced albumin, while the expanded plasma volume dilutes drug concentration; both effects combine to alter Vd and possibly reduce efficacy at standard doses \u2014 dose adjustment guided by therapeutic monitoring is prudent',\n 'Reduced albumin in pregnancy is fully compensated by the 40% increase in plasma volume, so total drug concentration and free fraction remain unchanged and no dose adjustment is required',\n 'The increase in plasma volume is the dominant effect; it dilutes drug concentration and reduces the free fraction, making the drug less effective and potentially toxic due to reduced clearance',\n 'Pregnancy has no clinically significant effect on protein binding for drugs that are less than 90% bound; only highly protein-bound drugs (>95%) require adjustment'\n ],\n exp: 'Pregnancy is a pharmacokinetic storm — virtually every parameter changes:<br><br><strong>Plasma volume<\/strong> +40% → dilution effect → lower plasma concentration for same dose → larger Vd → may need <em>higher<\/em> doses.<br><br><strong>Albumin<\/strong> ↓20% → reduced binding sites → free fraction rises → more pharmacologically active drug → but also more available for elimination.<span class=\"calc\">Baseline: 70% bound, 30% free<br>With 20% albumin fall: binding capacity reduced<br>Free fraction rises (exact amount depends on drug-specific binding constants)<br>Simultaneously: dilution from expanded plasma volume lowers total Cp<\/span><strong>Net effect:<\/strong> unpredictable without drug-specific data. These effects push in opposite directions and may partially cancel or compound. For NTI drugs (phenytoin, lithium, digoxin), pregnancy nearly always requires dose adjustment upward and therapeutic drug monitoring. Trap B (full compensation) is pharmacologically implausible — volume expansion dilutes drug but does not restore albumin binding sites. Trap C misassigns the direction of free-fraction change with volume expansion. The exam-safe answer: <strong>monitor levels, do not assume standard doses are adequate in late pregnancy<\/strong>.'\n }\n\n ];\n\n var answers = {}, answered = 0, shuffled = {}, done = false;\n\n function gid(s) { return document.getElementById(NS + '-' + s); }\n function byId(s) { return document.getElementById(s); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, t;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n t = a[i]; a[i] = a[j]; a[j] = t;\n }\n return a;\n }\n\n function countVal(v) {\n var n = 0, k;\n for (k in answers) { if (answers[k] === v) n++; }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, j, optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = byId(NS + '-pl' + qid);\n if (pl) { pl.className = 'mr-pip-line done'; }\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#1A5F7A ' + disp + '%, #B8D8E3 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [\n [5, 'Series closed perfectly. GTN anatomy, warfarin displacement, neonatal kinetics, the creatinine trap, pregnancy \\u2014 all owned.'],\n [4, 'Strong finish. One concept to consolidate \\u2014 the debrief has it. Seven rounds done.'],\n [3, 'Good base across the series. The creatinine trap (Q4) and protein binding displacement (Q2) are the ones to revisit before the Summative.'],\n [2, 'Two solid concepts to re-read: the portal vein anatomy in Q1 and the elderly creatinine trap in Q4. Both are exam staples.'],\n [0, 'Start with Q1 \\u2014 the GTN anatomy question is pure logic once you know the portal vein route. Then build from there.']\n ];\n gid('verdict').textContent = verdicts[4][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n<\/html>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,79],"tags":[83],"class_list":["post-37355","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-pharmacology","tag-neet-pg"],"yoast_head":"\n<title>Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… \" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-23T05:09:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-23T05:09:46+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations\",\"datePublished\":\"2026-08-23T05:09:06+00:00\",\"dateModified\":\"2026-08-23T05:09:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"},\"wordCount\":83,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"Pharmacology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\",\"name\":\"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-08-23T05:09:06+00:00\",\"dateModified\":\"2026-08-23T05:09:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/pharmacokinetics-bioavailability-protein-binding-special-populations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n","yoast_head_json":{"title":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","og_description":"Morning Rounds \u00b7 Pharmacokinetics \u00b7 Round 07 Numerical Series · Pharmacokinetics Morning Rounds · Round 07 of 07 Bioavailability, Protein Binding& Special Populations Series finale · First-pass, free drug fraction, pregnancy, paediatrics & the elderly 5 Questions +4 \/ −1 scoring Options reshuffled Submit for Debrief Series Complete 0% net Round 07 — Your Debrief… ","og_url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","og_site_name":"atsixty","article_published_time":"2026-08-23T05:09:06+00:00","article_modified_time":"2026-08-23T05:09:46+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations","datePublished":"2026-08-23T05:09:06+00:00","dateModified":"2026-08-23T05:09:46+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"},"wordCount":83,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["NEET-PG"],"articleSection":["Morning Rounds","Pharmacology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/","name":"Pharmacokinetics - Bioavailability, Protein Binding & Special Populations - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-08-23T05:09:06+00:00","dateModified":"2026-08-23T05:09:46+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/pharmacokinetics-bioavailability-protein-binding-special-populations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacokinetics – Bioavailability, Protein Binding & Special Populations"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37355"}],"version-history":[{"count":2,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355\/revisions"}],"predecessor-version":[{"id":37357,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37355\/revisions\/37357"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}